mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 19, Issue 1, Pages 1-12
Publisher
Bioscientifica
Online
2011-09-09
DOI
10.1530/erc-11-0072
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
- (2010) A Schayowitz et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
- (2010) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Update on radiation-based therapies for prostate cancer
- (2010) Young Kwok et al. CURRENT OPINION IN ONCOLOGY
- The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
- (2010) P. Saunders et al. HAEMATOLOGICA
- Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
- (2010) Nagata INTERNATIONAL JOURNAL OF ONCOLOGY
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
- (2010) Ankur Sharma et al. JOURNAL OF CLINICAL INVESTIGATION
- Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer
- (2009) Taro Matsuzaki et al. CANCER SCIENCE
- Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
- (2009) J. D. Murphy et al. CLINICAL CANCER RESEARCH
- Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
- (2009) A. S. Fung et al. CLINICAL CANCER RESEARCH
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
- (2009) K. E. Knudsen et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
- (2009) Kanishka Sircar et al. JOURNAL OF PATHOLOGY
- Regulation of Protein Synthesis by Ionizing Radiation
- (2009) S. Braunstein et al. MOLECULAR AND CELLULAR BIOLOGY
- Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
- (2009) O. Ekshyyan et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the androgen receptor pathway in prostate cancer
- (2008) Yu Chen et al. CURRENT OPINION IN PHARMACOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
- (2008) Todd M. Morgan et al. PROSTATE
- Mechanisms mediating androgen receptor reactivation after castration
- (2008) Xin Yuan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?
- (2008) Eric A. Klein et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started